A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death

Year: 2024

Type: article

Abstract: CD73 is the key ectoenzyme involved in the generation of AMP-derived adenosine, which contributes to immunosuppression in the MM BM milieu. Blocking CD73 activity with a potent, selective, orally bioavailable CD73 inhibitor ORIC-533 decreases adenosine generation, overcomes immune suppression, and restores immune cell-mediated MM cell lysis. Based on these preclinical studies, a multi-center clinical trial of ORIC-533 has been initiated in patients with relapsed refractory MM (NCT05227144).

Source: Blood Cancer Journal

DOI: 10.1038/s41408-024-01019-5

Institutions: Harvard University, Dana-Farber Cancer Institute, ORIC Pharmaceuticals, Inc. (United States), Dana-Farber/Harvard Cancer Center

Language: English

Topic: Adenosine and Purinergic Signaling

Subfield: Physiology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,990

Funders: Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, National Institutes of Health, National Cancer Institute

Awards: G1216594406, Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications, G669258595, Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma, Integrative Oncogenomics of Multiple Myeloma

OpenAlex ID: W4394615084